Tissue Engineering

Bone Solutions Inc. (BSI) receives FDA 510(K) clearance for worlds first and only magnesium-based bone void filler, OsteoCrete

Published in Medical Letter on the CDC and FDA, June 28th, 2009

Bone Solutions Inc. (BSI) announced that it has received FDA 510(k) clearance for the first device in its technology pipeline—a proprietary bone void filler, OsteoCrete™, which represents a critical milestone in the Company's efforts to establish a platform for its patented magnesium-based technology.

The Company expects this milestone to trigger its long-term plan to establish its platform as the 'one-stop bone-, tendon- and ligament-injectable, biodegradable adhesive technology' for surgeries at hospitals, clinics and other private surgical centers within the orthopedic industry.

"BSI's OsteoCrete™, now FDA-cleared for long-bone and pelvis...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2009-06-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry